Delgocitinib

德戈替尼

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameDelgocitinib
Drug Alias Name迪高替尼CorectimコレクチムCORECTIMAnzupgo +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsPalmoplantar pustulosisLichen Sclerosus et AtrophicusLichen Planus +[9] 
Global Approved IndicationsEczemaDermatitisDermatitis, Atopic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/01/23
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesJapan Tobacco (Hong Kong) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLeo Pharma Consultancy(Shanghai)Company LtdJapan Tobacco (Hong Kong) LtdIcahn School Of Medicine At Mount Sinai +[6] 
Inactive CompaniesN/A
Active IndicationsPalmoplantar pustulosisLichen Sclerosus et AtrophicusLichen Planus +[7] 
Inactive IndicationsAlopecia AreataLupus Erythematosus, Discoid

Other Information

ATC CodeD11AH
Related LinksKEGG